DiaCarta is a molecular diagnostics company with innovative technologies to transform patient care by precision diagnostics using liquid biopsy. Its novel XNA technology enhances high assay sensitivity by enriching mutant alleles in Sanger sequencing, qPCR, and NGS. With this, DiaCarta has developed its QClamps® tests and ColoScape™ colorectal cancer mutation test. Powered by its isobDNA™ technology that amplifies signals without RNA/DNA extraction or amplification, DiaCarta has developed its RadTox™ test to personalize radiotherapy and chemotherapy monitoring.